



## DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

- POLICY:** Diabetes – Victoza Drug Quantity Management Policy – Per Days
- Victoza® (liraglutide subcutaneous injection – Novo Nordisk, generic)

**REVIEW DATE:** 07/17/2024

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## **CIGNA NATIONAL FORMULARY COVERAGE:**

### **OVERVIEW**

Liraglutide subcutaneous (SC) injection (Victoza, generic), a glucagon-like peptide 1 (GLP-1) agonist, is indicated:<sup>1</sup>

- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric **patients ≥ 10 years of age with type 2 diabetes mellitus.**
- To **reduce the risk of major adverse cardiovascular events** (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

### **Dosing**

#### *Adult Dosing*

The recommended initial dose of liraglutide is 0.6 mg administered subcutaneous (SC) once daily (QD) for 1 week.<sup>1</sup> The 0.6 mg QD dose is not effective for glycemic control in adults; it is intended to be used to reduce gastrointestinal symptoms during initial titration. Following 1 week of dosing at 0.6 mg QD, the dose should be increased to 1.2 mg SC QD. After at least 1 week of treatment with 1.2 mg SC QD, the dose may be increased to the maximum recommended dose of 1.8 mg SC QD if additional glycemic control is required.

### *Pediatric Dosing*

In pediatric patients  $\geq 10$  years of age, the recommended initial dose of liraglutide is 0.6 mg SC QD.<sup>1</sup> After 1 week at the current dose, the dose may be increased in 0.6 mg increments if additional glycemic control is required. The maximum recommended dose is 1.8 mg SC QD.

If the patient misses a dose of liraglutide, they should resume the QD dosing regimen as prescribed with the next scheduled dose.<sup>1</sup> If more than 3 days have passed since the last dose of liraglutide, it should be reinitiated at the 0.6 mg QD dose to mitigate any gastrointestinal symptoms associated with treatment reinitiation. Then, liraglutide should be titrated at the discretion of the healthcare provider.

### **Availability**

Liraglutide (Victoza, generic) is supplied as an 18 mg/3 mL (6 mg/mL) prefilled pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg.<sup>1</sup> The pens are supplied in packages containing 2 or 3 pens each.

### **POLICY STATEMENT**

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of the liraglutide subcutaneous (SC) injection (Victoza, generic). Two quantity limits (Limit A and Limit B) are in place for liraglutide SC injection (Victoza, generic) and are outlined below. If the Drug Quantity Management rules are not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

**Diabetes – Victoza Drug Quantity Management Policy – Per Days product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.**

### **Drug Quantity Limit A**

<b>Product</b>	<b>Strength and Form</b>	<b>Retail Maximum Quantity Per 30 Days</b>	<b>Home Delivery Maximum Quantity Per 90 Days</b>
Victoza® (liraglutide SC injection, generic)	18 mg/3 mL pen (2-pack)	6 mL (2 pens)	18 mL (6 pens)
	18 mg/3 mL pen (3-pack)	9 mL (3 pens)	27 mL (9 pens)

SC – Subcutaneous.

### **CRITERIA A**

Liraglutide subcutaneous (SC) injection (Victoza, generic) 18 mg/3 mL pen (2-pack and 3-pack)

No overrides recommended.

## Drug Quantity Limit B

Product	Strength and Form	Retail and Home Delivery Maximum Quantity Per 21 Days
Victoza® (liraglutide SC injection, generic)	18 mg/3 mL pen (2- pack)	<b>ONE claim collectively for ONE GLP-1 agonist or GLP-1/GIP agonist may be approved every 21 days.<sup>a</sup></b>
	18 mg/3 mL pen (3- pack)	

SC – Subcutaneous; GLP-1 – Glucagon-like peptide-1; GIP – Glucose-dependent insulinotropic peptide

<sup>a</sup> Refer to Appendix A for a list of the drugs included in this limit.

## CRITERIA B

**Note:** The criteria below apply only to Quantity Limit B.

### Liraglutide subcutaneous (SC) injection (Victoza, generic) 18 mg/3 mL pen (2-pack)

1. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Victoza, approve a one-time override for 6 mL (2 pens) at retail or 18 mL (6 pens) at home delivery.

**Note:** Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin® (lixisenatide SC injection), Bydureon BCise® (exenatide extended-release SC injection), Byetta® (exenatide SC injection), Mounjaro® (tirzepatide SC injection), Ozempic® (semaglutide SC injection), Rybelsus® (semaglutide tablets), Trulicity® (dulaglutide SC injection), Saxenda® (liraglutide SC injection), Wegovy® (semaglutide SC injection), Zepbound® (tirzepatide SC injection).

### Liraglutide SC injection (Victoza, generic) 18 mg/3 mL pen (3-pack)

1. If the patient is switching from another GLP-1 agonist or GLP-1/GIP agonist to Victoza, approve a one-time override for 9 mL (3 pens) at retail or 27 mL (9 pens) at home delivery.

**Note:** Other GLP-1 agonists and GLP-1/GIP agonists include Adlyxin® (lixisenatide SC injection), Bydureon BCise® (exenatide extended-release SC injection), Byetta® (exenatide SC injection), Mounjaro® (tirzepatide SC injection), Ozempic® (semaglutide SC injection), Rybelsus® (semaglutide tablets), Trulicity® (dulaglutide SC injection), Saxenda® (liraglutide SC injection), Wegovy® (semaglutide SC injection), Zepbound® (tirzepatide SC injection).

## REFERENCES

1. Victoza® subcutaneous injection [prescribing information]. Plainsboro, NJ: Novo Nordisk; July 2023.

## HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	New policy created to add additional quantity limits to approve ONE claim collectively for ONE glucagon-like peptide-1 (GLP-1) agonist or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist every 21 days at retail or home delivery. New clinical overrides	07/17/2024

	apply to these limits. Existing "Per Days" quantity limits were not changed and no overrides apply.	
--	---	--

## APPENDIX A

**Table 1. GLP-1 Agonists and GLP-1/GIP Agonists.**

<b>Brand (Generic Name)</b>	<b>Dosage Form</b>
Adlyxin® (lixisenatide SC injection)	10-20 mcg Starter Pack (discontinued) 20 mcg Maintenance Pack (discontinued)
Bydureon® (exenatide extended-release SC injection)	2 mg/0.65 mL pen
Bydureon BCise® (exenatide extended-release SC injection)	2 mg/0.85 mL prefilled auto-injector
Byetta® (exenatide SC injection)	5 mcg/0.02 mL dose pen (1.2 mL) 10 mcg/0.04 mL dose pen (2.4 mL)
Mounjaro® (tirzepatide SC injection)	2.5 mg/0.5 mL pen 5 mg/0.5 mL pen 7.5 mg/0.5 mL pen 10 mg/0.5 mg pen 12.5 mg/0.5 mL pen 15 mg/0.5 mL pen
Ozempic® (semaglutide SC injection)	0.25 mg and 0.5 mg dose pen (2 mg/1.5 mL) [discontinued] 0.25 mg and 0.5 mg dose pen (2 mg/3 mL) 1 mg dose pen (2 mg/1.5 mL) [discontinued] 1 mg dose pen (4 mg/3 mL) 2 mg dose pen (8 mg/3 mL)
Rybelsus® (semaglutide tablets)	3 mg tablet 7 mg tablet 14 mg tablet
Saxenda® (liraglutide SC injection)	18 mg/3 mL pen
Trulicity® (dulaglutide SC injection)	0.75 mg/0.5 mL pen 1.5 mg/0.5 mL pen 3 mg/0.5 mL pen 4.5 mg/0.5 mL pen
Victoza® (liraglutide SC injection, generic)	18 mg/3 mL pen (2-pack) 18 mg/3 mL pen (3-pack)
Wegovy® (semaglutide SC injection)	0.25 mg/0.5 mL pen 0.5 mg/0.5 mL pen 1 mg/0.5 mL pen 1.7 mg/0.75 mL pen 2.4 mg/0.75 mL pen
Zepbound® (tirzepatide SC injection)	2.5 mg/0.5 mL pen 5 mg/0.5 mL pen 7.5 mg/0.5 mL pen 10 mg/0.5 mL pen 12.5 mg/0.5 mL pen 15 mg/0.5 mL pen

GLP – Glucagon-like peptide-1; GIP – Glucose-dependent insulinotropic polypeptide; SC – Subcutaneous.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc.,

Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. ©  
2024 The Cigna Group.